| Characteristics . | Total . | Patients aged ≥65 years . | ||||
|---|---|---|---|---|---|---|
| Non-PCIa (n = 95) . | PCIa (n = 139) . | P-value . | Non-PCIa (n = 35) . | PCIa (n = 33) . | P-value . | |
| Gender | 0.469 | 0.651 | ||||
| Male | 81 (85.3) | 123 (88.5) | 31 (88.57) | 28 (84.85) | ||
| Female | 14 (14.7) | 16 (11.5) | 4 (11.43) | 5 (15.15) | ||
| Age | 0.030 | - | ||||
| <65 years | 60 (63.2) | 106 (76.3) | – | – | ||
| ≥65 years | 35 (36.8) | 33 (23.7) | – | – | ||
| Median (range) | 62 years | 60 years | 67 years | 68 years | ||
| (40–77) | (34–75) | (65–77) | (65–75) | |||
| LDH | 0.006 | 0.041 | ||||
| <400 U/l | 34 (36.6) | 76 (55.1) | 10 (28.6) | 17 (53.1) | ||
| ≥400 U/l | 59 (63.4) | 62 (44.9) | 25 (71.4) | 15 (46.9) | ||
| Median (range) | 459 U/l | 388 U/l | 470 U/l | 391 U/l | ||
| (237–1402) | (224–1078) | (269–758) | (237–927) | |||
| Performance Status | 0.054 | 0.594 | ||||
| 0 | 7 (7.4) | 22 (15.8) | 2 (5.7) | 3 (9.1) | ||
| 1–2 | 88 (92.6) | 117 (84.2) | 33 (94.3) | 30 (90.9) | ||
| cT | 0.565 | 0.242 | ||||
| 0–2 | 80 (84.2) | 113 (81.3) | 32 (91.4) | 27 (81.8) | ||
| 3–4 | 15 (15.8) | 26 (18.7) | 3 (8.6) | 6 (18.2) | ||
| cN | 0.274 | 0.346 | ||||
| 0–1 | 20 (21.1) | 38 (27.3) | 10 (28.6) | 13 (39.4) | ||
| 2–3 | 75 (78.9) | 101 (72.7) | 25 (71.4) | 20 (60.6) | ||
| Stage | 0.543 | 0.492 | ||||
| I–II | 20 (21.1) | 34 (24.5) | 10 (28.6) | 12 (36.4) | ||
| III | 75 (78.9) | 105 (75.5) | 25 (71.4) | 21 (63.6) | ||
| Tumor volume | 0.337 | 0.270 | ||||
| <50 ml | 15 (21.7) | 50 (51.0) | 8 (47.1) | 15 (55.6) | ||
| ≥50 ml | 21 (58.3) | 48 (49.0) | 9 (52.9) | 12 (44.4) | ||
| Median (range) | 53.1 ml | 48.5 ml | 53.2 ml | 45.0 ml | ||
| (21.8–139.8) | (11.4–172.4) | (21.8–115.9) | (11.4–146.4) | |||
| Radiotherapy dose | <0.001 | 0.001 | ||||
| 44 Gy | 62 (65.3) | 39 (28.1) | 21 (60.0) | 7 (21.2) | ||
| 52.5 Gy | 33 (34.7) | 100 (71.9) | 14 (40.0) | 26 (78.8) | ||
| Treatment schedule | 0.004 | 0.475 | ||||
| Early | 71 (74.7) | 78 (56.1) | 20 (57.1) | 16 (48.5) | ||
| Late | 24 (25.3) | 61 (43.9) | 15 (42.9) | 17 (51.5) | ||
| Characteristics . | Total . | Patients aged ≥65 years . | ||||
|---|---|---|---|---|---|---|
| Non-PCIa (n = 95) . | PCIa (n = 139) . | P-value . | Non-PCIa (n = 35) . | PCIa (n = 33) . | P-value . | |
| Gender | 0.469 | 0.651 | ||||
| Male | 81 (85.3) | 123 (88.5) | 31 (88.57) | 28 (84.85) | ||
| Female | 14 (14.7) | 16 (11.5) | 4 (11.43) | 5 (15.15) | ||
| Age | 0.030 | - | ||||
| <65 years | 60 (63.2) | 106 (76.3) | – | – | ||
| ≥65 years | 35 (36.8) | 33 (23.7) | – | – | ||
| Median (range) | 62 years | 60 years | 67 years | 68 years | ||
| (40–77) | (34–75) | (65–77) | (65–75) | |||
| LDH | 0.006 | 0.041 | ||||
| <400 U/l | 34 (36.6) | 76 (55.1) | 10 (28.6) | 17 (53.1) | ||
| ≥400 U/l | 59 (63.4) | 62 (44.9) | 25 (71.4) | 15 (46.9) | ||
| Median (range) | 459 U/l | 388 U/l | 470 U/l | 391 U/l | ||
| (237–1402) | (224–1078) | (269–758) | (237–927) | |||
| Performance Status | 0.054 | 0.594 | ||||
| 0 | 7 (7.4) | 22 (15.8) | 2 (5.7) | 3 (9.1) | ||
| 1–2 | 88 (92.6) | 117 (84.2) | 33 (94.3) | 30 (90.9) | ||
| cT | 0.565 | 0.242 | ||||
| 0–2 | 80 (84.2) | 113 (81.3) | 32 (91.4) | 27 (81.8) | ||
| 3–4 | 15 (15.8) | 26 (18.7) | 3 (8.6) | 6 (18.2) | ||
| cN | 0.274 | 0.346 | ||||
| 0–1 | 20 (21.1) | 38 (27.3) | 10 (28.6) | 13 (39.4) | ||
| 2–3 | 75 (78.9) | 101 (72.7) | 25 (71.4) | 20 (60.6) | ||
| Stage | 0.543 | 0.492 | ||||
| I–II | 20 (21.1) | 34 (24.5) | 10 (28.6) | 12 (36.4) | ||
| III | 75 (78.9) | 105 (75.5) | 25 (71.4) | 21 (63.6) | ||
| Tumor volume | 0.337 | 0.270 | ||||
| <50 ml | 15 (21.7) | 50 (51.0) | 8 (47.1) | 15 (55.6) | ||
| ≥50 ml | 21 (58.3) | 48 (49.0) | 9 (52.9) | 12 (44.4) | ||
| Median (range) | 53.1 ml | 48.5 ml | 53.2 ml | 45.0 ml | ||
| (21.8–139.8) | (11.4–172.4) | (21.8–115.9) | (11.4–146.4) | |||
| Radiotherapy dose | <0.001 | 0.001 | ||||
| 44 Gy | 62 (65.3) | 39 (28.1) | 21 (60.0) | 7 (21.2) | ||
| 52.5 Gy | 33 (34.7) | 100 (71.9) | 14 (40.0) | 26 (78.8) | ||
| Treatment schedule | 0.004 | 0.475 | ||||
| Early | 71 (74.7) | 78 (56.1) | 20 (57.1) | 16 (48.5) | ||
| Late | 24 (25.3) | 61 (43.9) | 15 (42.9) | 17 (51.5) | ||
PCI = prophylactic cranial irradiation, LDH = lactate dehydrogenase, U/l = units per liter.
aValues are numbers (%).
| Characteristics . | Total . | Patients aged ≥65 years . | ||||
|---|---|---|---|---|---|---|
| Non-PCIa (n = 95) . | PCIa (n = 139) . | P-value . | Non-PCIa (n = 35) . | PCIa (n = 33) . | P-value . | |
| Gender | 0.469 | 0.651 | ||||
| Male | 81 (85.3) | 123 (88.5) | 31 (88.57) | 28 (84.85) | ||
| Female | 14 (14.7) | 16 (11.5) | 4 (11.43) | 5 (15.15) | ||
| Age | 0.030 | - | ||||
| <65 years | 60 (63.2) | 106 (76.3) | – | – | ||
| ≥65 years | 35 (36.8) | 33 (23.7) | – | – | ||
| Median (range) | 62 years | 60 years | 67 years | 68 years | ||
| (40–77) | (34–75) | (65–77) | (65–75) | |||
| LDH | 0.006 | 0.041 | ||||
| <400 U/l | 34 (36.6) | 76 (55.1) | 10 (28.6) | 17 (53.1) | ||
| ≥400 U/l | 59 (63.4) | 62 (44.9) | 25 (71.4) | 15 (46.9) | ||
| Median (range) | 459 U/l | 388 U/l | 470 U/l | 391 U/l | ||
| (237–1402) | (224–1078) | (269–758) | (237–927) | |||
| Performance Status | 0.054 | 0.594 | ||||
| 0 | 7 (7.4) | 22 (15.8) | 2 (5.7) | 3 (9.1) | ||
| 1–2 | 88 (92.6) | 117 (84.2) | 33 (94.3) | 30 (90.9) | ||
| cT | 0.565 | 0.242 | ||||
| 0–2 | 80 (84.2) | 113 (81.3) | 32 (91.4) | 27 (81.8) | ||
| 3–4 | 15 (15.8) | 26 (18.7) | 3 (8.6) | 6 (18.2) | ||
| cN | 0.274 | 0.346 | ||||
| 0–1 | 20 (21.1) | 38 (27.3) | 10 (28.6) | 13 (39.4) | ||
| 2–3 | 75 (78.9) | 101 (72.7) | 25 (71.4) | 20 (60.6) | ||
| Stage | 0.543 | 0.492 | ||||
| I–II | 20 (21.1) | 34 (24.5) | 10 (28.6) | 12 (36.4) | ||
| III | 75 (78.9) | 105 (75.5) | 25 (71.4) | 21 (63.6) | ||
| Tumor volume | 0.337 | 0.270 | ||||
| <50 ml | 15 (21.7) | 50 (51.0) | 8 (47.1) | 15 (55.6) | ||
| ≥50 ml | 21 (58.3) | 48 (49.0) | 9 (52.9) | 12 (44.4) | ||
| Median (range) | 53.1 ml | 48.5 ml | 53.2 ml | 45.0 ml | ||
| (21.8–139.8) | (11.4–172.4) | (21.8–115.9) | (11.4–146.4) | |||
| Radiotherapy dose | <0.001 | 0.001 | ||||
| 44 Gy | 62 (65.3) | 39 (28.1) | 21 (60.0) | 7 (21.2) | ||
| 52.5 Gy | 33 (34.7) | 100 (71.9) | 14 (40.0) | 26 (78.8) | ||
| Treatment schedule | 0.004 | 0.475 | ||||
| Early | 71 (74.7) | 78 (56.1) | 20 (57.1) | 16 (48.5) | ||
| Late | 24 (25.3) | 61 (43.9) | 15 (42.9) | 17 (51.5) | ||
| Characteristics . | Total . | Patients aged ≥65 years . | ||||
|---|---|---|---|---|---|---|
| Non-PCIa (n = 95) . | PCIa (n = 139) . | P-value . | Non-PCIa (n = 35) . | PCIa (n = 33) . | P-value . | |
| Gender | 0.469 | 0.651 | ||||
| Male | 81 (85.3) | 123 (88.5) | 31 (88.57) | 28 (84.85) | ||
| Female | 14 (14.7) | 16 (11.5) | 4 (11.43) | 5 (15.15) | ||
| Age | 0.030 | - | ||||
| <65 years | 60 (63.2) | 106 (76.3) | – | – | ||
| ≥65 years | 35 (36.8) | 33 (23.7) | – | – | ||
| Median (range) | 62 years | 60 years | 67 years | 68 years | ||
| (40–77) | (34–75) | (65–77) | (65–75) | |||
| LDH | 0.006 | 0.041 | ||||
| <400 U/l | 34 (36.6) | 76 (55.1) | 10 (28.6) | 17 (53.1) | ||
| ≥400 U/l | 59 (63.4) | 62 (44.9) | 25 (71.4) | 15 (46.9) | ||
| Median (range) | 459 U/l | 388 U/l | 470 U/l | 391 U/l | ||
| (237–1402) | (224–1078) | (269–758) | (237–927) | |||
| Performance Status | 0.054 | 0.594 | ||||
| 0 | 7 (7.4) | 22 (15.8) | 2 (5.7) | 3 (9.1) | ||
| 1–2 | 88 (92.6) | 117 (84.2) | 33 (94.3) | 30 (90.9) | ||
| cT | 0.565 | 0.242 | ||||
| 0–2 | 80 (84.2) | 113 (81.3) | 32 (91.4) | 27 (81.8) | ||
| 3–4 | 15 (15.8) | 26 (18.7) | 3 (8.6) | 6 (18.2) | ||
| cN | 0.274 | 0.346 | ||||
| 0–1 | 20 (21.1) | 38 (27.3) | 10 (28.6) | 13 (39.4) | ||
| 2–3 | 75 (78.9) | 101 (72.7) | 25 (71.4) | 20 (60.6) | ||
| Stage | 0.543 | 0.492 | ||||
| I–II | 20 (21.1) | 34 (24.5) | 10 (28.6) | 12 (36.4) | ||
| III | 75 (78.9) | 105 (75.5) | 25 (71.4) | 21 (63.6) | ||
| Tumor volume | 0.337 | 0.270 | ||||
| <50 ml | 15 (21.7) | 50 (51.0) | 8 (47.1) | 15 (55.6) | ||
| ≥50 ml | 21 (58.3) | 48 (49.0) | 9 (52.9) | 12 (44.4) | ||
| Median (range) | 53.1 ml | 48.5 ml | 53.2 ml | 45.0 ml | ||
| (21.8–139.8) | (11.4–172.4) | (21.8–115.9) | (11.4–146.4) | |||
| Radiotherapy dose | <0.001 | 0.001 | ||||
| 44 Gy | 62 (65.3) | 39 (28.1) | 21 (60.0) | 7 (21.2) | ||
| 52.5 Gy | 33 (34.7) | 100 (71.9) | 14 (40.0) | 26 (78.8) | ||
| Treatment schedule | 0.004 | 0.475 | ||||
| Early | 71 (74.7) | 78 (56.1) | 20 (57.1) | 16 (48.5) | ||
| Late | 24 (25.3) | 61 (43.9) | 15 (42.9) | 17 (51.5) | ||
PCI = prophylactic cranial irradiation, LDH = lactate dehydrogenase, U/l = units per liter.
aValues are numbers (%).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
